Opnurasib
Product Specifications
UNSPSC Description
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity[1][2].
Target Antigen
PERK; Ras
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;GPCR/G Protein;MAPK/ERK Pathway
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/opnurasib.html
Smiles
O=C(C=C)N1CC2(C1)CC(N3N=C(C4=CC=C5C(C=NN5C)=C4)[C@]([C@]6=C(Cl)C(C)=CC7=C6C=NN7)=C3C)C2
Molecular Weight
526.03
References & Citations
[1]LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.|[2][2] Weiss A, Lorthiois E, Barys L, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022;candisc.0158.2022.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-139612/Opnurasib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-139612/Opnurasib-SDS-MedChemExpress.pdf
CAS Number
2653994-08-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
